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Sex differences in gout characteristics:
tailoring care for women and men
Leslie R. Harrold1*, Carol J. Etzel2,3, Allan Gibofsky4, Joel M. Kremer5, Michael H. Pillinger6, Kenneth G. Saag7,
Naomi Schlesinger8, Robert Terkeltaub9, Vanessa Cox2 and Jeffrey D. Greenberg2,6
Abstract
Background: To characterize the differences between women and men with gout.
Methods: We analyzed a US national cohort of gout patients cared for by rheumatologists.
Results: Compared with the 1012 men with gout, women with gout (n = 262) were older (71 vs. 61 years, p < 0.
001) and had a greater burden of comorbid conditions (p < 0.001 for hypertension, diabetes, renal disease and
obesity). Risk factors for gout differed with women more often taking diuretics (p < 0.001), while men more
frequently had dietary triggers (p < 0.05).
Conclusions: The profiles of women and men with gout are markedly different, suggesting a need to tailor
treatment recommendations.
Keywords: Gout, Comorbidity, Gender, Quality of Care
Background
Gout is the most common inflammatory arthritis, affecting
approximately 8.3 million Americans (6.1 million men and
2.2 million women) [1]. Gout prevalence has been increas-
ing over the last half century, due to the aging of the popu-
lation, increased use of medications that can trigger gout,
and the obesity epidemic [2]. Gout is associated with a
reduced quality of life, functional impairment, reduced
productivity and a higher risk of death [3, 4]. Accumulating
evidence suggests that gout is an independent risk factor
for cardiovascular morbidity and mortality in both women
and men [5].
While gout has been studied for centuries, most
research has focused on men. For example, there have
been very few studies that have examined the epidemi-
ology of gout based on sex. Those that have included
relatively small numbers of women [6, 7] or lacked gout-
specific details [8]. Even clinical trials of therapeutic
agents for the acute and chronic management of gout
included very few women [9–11]. Given the prevalence
and impact of gout, it is essential to identify the factors
that impede optimal gout management in both women
and men in order to provide tailored treatment
recommendations.
In 2012, CORRONA (the Consortium of Rheumatology
Researchers of North America) created a national gout
registry in which rheumatologists enrolled their gout
patients with longitudinal assessment. Within this setting,
our objective was to compare women and men with gout
to see whether they differed in terms of comorbid condi-
tions associated with gout and risk factors for gout flares.
We hypothesized that the patient profile of women with
gout would be very different as compared to men with the
condition.
Methods
Data source and population
CORRONA creates prospective observational cohorts of
arthritis patients enrolled by participating rheumatolo-
gists in both academic and private practice sites. There
were 1273 patients with rheumatologist-diagnosed gout
based on the 1977 diagnostic criteria [12] (the registry
predated the 2015 American College of Rheumatology
Gout Classification criteria) and enrolled in the CORRONA
registry database between 11/1/2012 and 3/31/2014 from
34 rheumatology practices across 20 states with 76
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participating rheumatologists. Approvals for data collection
and analyses were obtained for academic and private prac-
tice sites from local and central institutional review boards,
respectively.
Measures and data collection
Data were collected from patients and their treating rheu-
matologists using standard clinical research forms based
on the American College of Rheumatology [13] treatment
recommendations. Information collected included demo-
graphics, comorbid conditions, gout presentation, disease
severity and activity, family history, body mass index
(BMI), dietary intake over the past week, use of medica-
tions that can raise serum urate level (e.g., diuretics), use
of medications for acute gouty inflammation (nonsteroid
anti-inflammatory drugs [NSAIDs], colchicine, steroids)
and urate-lowering therapy (ULT) including uricosurics,
xanthine oxidase inhibitors, and recombinant uricase
[pegloticase]. Documentation included physician exam
findings of tophi and inflamed joints, physician and
patient global assessments of disease activity, patient as-
sessment of pain, the Health Assessment Questionnaire
(HAQ) assessing physical function, and serum urate levels
(SUA) from laboratory tests obtained within 10 days of
the clinical encounter (this data is not mandated by the
study protocol). Patients reported the number of days in
the past 3 months there were unable to perform their
usual activity. Health care utilization data, including
gout hospitalizations within the last 3 years as well as
Emergency Room and/or outpatients visits in the past
12 months for gout flares, were gathered. Additionally
patients reported how many flares they managed them-
selves without seeing a health care professional.
Comparison by sex
We compared patients’ baseline characteristics at the
time of enrollment, including demographics, gout-
related comorbid conditions and medications, gout char-
acteristics, contributing medical conditions and medica-
tions. We compared dietary factors associated with gout
flares in men and women in terms of any intake over the
past week of beef, pork, seafood and alcohol, as well as
the number of weekly servings consumed. We also eval-
uated rate of use of ULT in the subset of subjects who
met ACR criteria for urate lowering (e.g., 2 or more gout
flares/year, presence of tophi, history of kidney stones or
presence of chronic kidney disease (CKD; stage 3 or
greater).
Statistical analysis
We use a cross-sectional study design, evaluating patients
at the time of enrollment. Descriptive statistics were
performed using t tests and chi square tests or Fisher exact
tests as appropriate. As a sensitivity analysis, when
examining the burden of comorbidity between the 2 sexes,
we used 3 propensity score (PS) approaches to balance the
differences in the ages and disease duration of the women
and men with gout. We conducted these sensitivity ana-
lyses to address a potential concern that differences in
comorbidity burden could have been related to sex differ-
ences in age (women were on average 10 years older than
men) or disease duration (men had on average 5 more
years of gout) The PS approaches allow us to compare
women and men with similar demographic profiles. We
used 3 approaches to assess the robustness of our findings.
For approach #1, we derived a PS using age and disease
duration and used PS trimming to excluded patients with a
PS score in the <5 percentile and >95 percentile range. For
approach #2, we included only those patients who fell in-
side the area of common support using age and disease
duration separately and then used PS trimming. Approach
#3 included only those patients with a conservative com-
mon support with PS trimming so that the resulting age
and disease duration characteristics of the women and
men with gout were within 3 years. All 3 approaches gave
similar results to the unadjusted analyses. Given the reduc-
tion in the sample size with each of these 3 approaches, we
show the unadjusted results in the body of the manuscript
but provide the results of the PS approaches in Additional
file 1: Table S1. To explore if there were dietary differences
between men and women, we conducted adjusted logistic
(yes/no dietary intake) and ordinal logistic regression
models (0, 1, 2+ servings per week of dietary intake) con-
trolling for age, BMI, duration of gout, comorbidity burden
[hypertension, diabetes, renal disease, hyperlipidemia],
HCTZ use, other diuretic use and current use of a urate-
lowering drug. Sex based comparison for functional status
was adjusted for age and presented herein. Lastly ULT use
was explored in those who met criteria for treatment based
on 2 or more attacks in 12 months or presence of tophi
(dosages provided in Additional file 2: Table S2).
Results
There were 262 women and 1011 men enrolled into the
registry meeting ACR criteria for gout [12] during the
study time period. Women were approximately 10 years
older than the men (71.2 vs. 60.9, p < 0.0001; Table 1).
Additionally, women were less likely to be white (88%
vs. 94%, p = 0.002) or to have private insurance (58% vs.
75%, p < 0.001). The overall burden of rheumatologist re-
ported comorbid conditions was greater in women in
both the overall cohort (Table 1) and PS trimmed sub-
sets (Additional file 1: Table S1). Women were more im-
paired in terms of days being unable to perform usual
work and activities as well as the HAQ score using age
adjusted estimates. Activity and HAQ discrepancies
persisted after adjusting for comorbidity and duration of
gout (Additional file 1: Table S1). Obesity and diuretic
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Table 1 Baseline demographic and gout characteristics
Characteristics Women Men P value
N = 262 N = 1011
Demographics
Age (mean years, SD) 71.2 (±10.7) 60.9 (±13.5) <0.0001
Race (White n, %) 219 (84) 897 (89) 0.024
Private insurance (n, %) 152 (58) 757 (75) <0.001
Comorbid conditions
BMI (mean, SD) 33.5 (±7.8) 31.9 (±6.5) 0.001
Osteoarthritis (n, %) 120 (46) 256 (25) <0.001
Other inflammatory arthritis (n,%) 19 (7) 34 (3) <0.001
Medical comorbidities (n,%)
Heart disease 41 (16) 147 (14) 0.652
Hypertension 201 (77) 574 (57) <0.001
Diabetes mellitus 73 (28) 168 (17) <0.001
Renal disease 64 (24) 136 (13) <0.001
Hyperlipidemia 120 (46) 394 (39) 0.045
Peripheral arterial disease 2 (1) 13 (1) 0.485
Functional Status (mean, SD)
Number of days unable to do usual work/activities in the prior 3 months 11.1 (±23.7) 6.9 (±195) 0.003
Health Assessment Questionnaire
Age adjusted means 0.59 (±0.11) 0.49 (±0.13) <0.001
Medications that may trigger gout (n, %)
Aspirin 76 (29) 285 (28) 0.794
HCTZ 51 (20) 105 (10) <0.001
Diuretics other than HCTZ 83 (32) 116 (11) <0.001
Gout characteristics
Family history (n, %) 180 (69) 682 (67) 0.701
Crystal proven (n, %) 65 (25) 346 (34) 0.004
Duration of gout (mean, SD) 6.1 (±7.1) 11.0 (±9.8) <0.0001
Maximum serum uric acid (mean, SD) 8.8 (±2.3) 8.7 (±2.1) 0.481
Current serum uric acid (mean, SD)a 5.9 (±2.6) 6.0 (±1.9) 0.449
Presence of tophi (n, %) 60 (23) 224 (22) 0.791
Contraindications for treatment with: 11 (10) 66 (16) 0.0.170
NSAIDS 80 (31) 206 (20) <0.001
Colchicine 32 (12) 61 (6) 0.001
Flare frequency in prior 12 months (mean, SD) 3.5 (±6.4) 3.7 (±8.2) 0.692
Health care utilization due to gout (n, %)
Proportion of patients with hospitalizations for gout in the past 3 years 7 (3) 19 (2)
Proportion with an ER visit for a gout flare in the past 12 months 37 (14) 118 (12) 0.275
Proportion with an outpatient physician visit for a gout flare in the past 12 months 124 (48) 479 (48) 0.918
Frequency of health care utilization for a flare in the prior 12 months:
ER visits (mean, SD) 0.32 (±1.17) 0.26 (1.49) 0.560
Outpatient encounters (mean, SD) 1.40 (±2.64) 1.30 (±2.68) 0.613
alaboratory data were available for 215 women and 870 men with gout
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use were also more common in women. Gout character-
istics at initial clinical presentation (data not shown)
were similar with respect to podagra, monoarthritis, and
polyarthritis. Additionally, both the maximum and most
recent serum sUA levels were similar, as well as the
prevalence of tophi, flare frequency and gout related
health care utilization. Women’s gout was less likely to
be crystal proven (25% vs. 34%, p = 0.004). Patterns of
dietary intake differed based on sex. Men were more
likely to report intake of beef, pork, seafood, beer, wine
and hard liquor in unadjusted and adjusted analyses
(Fig. 1) as well as a greater number of servings of those
items (Additional file 3: Figure S1).
Medications including colchicine, NSAIDs, and
glucocorticoids, which can be used either for an acute
gouty flare or for prophylaxis when initiating a ULT,
were prescribed at similar rates in women and men
(Table 2). In addition, over-the-counter supplements
for gout were used in both women and men. However,
women had greater use of acetaminophen and opioid
analgesics. Among those who met criteria for ULT,
women were as likely as men to receive it in both un-
adjusted (77% vs. 83%, p = 0.10) or PS adjusted (OR
0.70, 95% confidence interval 0.43–1.15) analyses.
Women were more likely to receive febuxostat, while
men more likely allopurinol (Table 2).
Discussion
Using a national gout registry, we were able to compare
women and men with gout and identify differences in
patient profiles with respect to gout-related burden of
comorbid disease, contributing medical conditions,
medications and diet. Even after using PS trimming tech-
niques to balance the patient populations in terms of age
and duration of gout, women had a greater burden of
musculoskeletal and medical comorbid illness as well as
functional impairment. Factors that contribute to gout,
including obesity, diuretic medications and diet differed
by sex. Women more often had renal disease, and
concomitant use of thiazides and/or other diuretics. In
contrast, men were more likely to report intake of foods
associated with both the development of gout and gout
flares, including beef, pork, seafood, and alcohol. The
most striking difference was seen in the intake of alcohol.
This does reflect national trends in the US that demon-
strate that men consume greater quantities of alcohol
Fig. 1 Comparison of the dietary factors that influence gout in women and men. The results are adjusted for age, BMI, duration of gout, comorbidity
burden [hypertension, diabetes, renal disease, hyperlipidemia], HCTZ use, other diuretic use and current use of a urate-lowering drug
Table 2 Medications and supplements to treat gout
Medicationa Women Men P value
N = 262 N = 1012
Acute/prophylactic gout medications (n, %)
Colchicine 86 (33) 366 (36) 0.314
Oral steroids 34 (13) 137 (14) 0.813
NSAIDs 63 (24) 283 (28) 0.204
Analgesic medications (n, %)
Acetaminophen 34 (13) 51 (5) <0.001
Opioid type pain relievers 40 (15) 76 (8) <0.001
Over the counter supplements for gout (use in the past week) (n, %)
Cherry Juice 21 (8) 111 (11) 0.161
Vitamin C 59 (23) 225 (22) 0.927
Turmeric 4 (2) 24 (2) 0.405
Chronic gout medications in those who are candidates
Candidates 164 558
Any ULT use 127 (77) 488 (83.0) 0.103
Allopurinol 84 (51) 378 (64) 0.002
Febuxostat 42 (26) 95 (17) 0.002
aNSAIDs nonsteroidal anti-inflammatory drugs, ULT urate lowering therapy
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overall as compared to women with beer as the top
choice for men while women drinkers have a preference
for wine [14].
Our study is similar to others demonstrating women
with gout to be older with a greater burden of comorbid
illness, and less likely to have their disease proven by
crystal diagnosis [6–8]. It is unclear whether lack of
crystal confirmation was due to women being less likely
offered the procedure versus more likely to decline hav-
ing it performed. Alternatively, the presentation of
women might have been more definitively consistent
with the diagnosis of gout and thus the rheumatologist
did not pursue further testing. There were differences in
the use of anti-inflammatory and analgesic medications,
with women were more likely to be receiving acetamino-
phen and narcotics. However, these medications may
have been used for other arthritic or painful conditions.
While patients of both sexes should receive care consist-
ent with “best practices”, our observations can help pro-
viders to prioritize which factors to explore in terms of
contributing to gout in men and women. We anticipate
that that patient sex will influence the management of
gout. For women, the greater prevalence of increased BMI
and diuretic use in this subset suggests this will need to be
targeted for intervention. Weight loss has been shown to
decrease gout flares and can improve the management of
the associated comorbid conditions such as osteoarthritis
and diabetes [15, 16]. For men with gout, a modification
of urate-generating dietary intake will need to be pursued
given the association with gout flares consistent with
treatment recommendations [13, 17–19].
An important strength of this study is that the registry
includes rich clinical data on a national sample of gout
patients cared for by rheumatologists. Limitations
include the study cohort may not be a representative
sample of US gout patients, although that seems less
likely given the comparisons to other national gout pop-
ulations [8]. Since this is not an inception cohort, we
also could not assess the true baseline characteristics of
patients at the time of gout diagnosis. However to
address this limitation, we used PS methodology to
explore the impact of imbalance in age and disease dur-
ation between the sexes and found similar findings.
Conclusions
In conclusion, this national cohort demonstrates that the
gout patient profile differs in women as compared to
men. Potentially modifiable factors such as BMI, diuretic
use and diet differ by sex. Additionally, the coexistence
of comorbidities that influence the management of the
condition, such as renal disease and diabetes, are much
more common in women as compared to men. A better
understanding of sex differences in gout patient profiles
will provide a foundation for tailored treatment recom-
mendations by providers.
Additional files
Additional file 1: Table S1. Baseline characteristics. (DOCX 15 kb)
Additional file 2: Table S2. Dosing of urate-lowering therapies among
eligible patients. (DOCX 12 kb)
Additional file 3: Figure S1. Comparison of the dietary servings
among women and men with gout. The p values represent adjusted
analyses adjusting for age, BMI, duration of gout, comorbidity burden
[hypertension, diabetes, renal disease, hyperlipidemia], HCTZ use, other
diuretic use and current use of a urate-lowering drug. (TIF 320 kb)
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